Fintech PR
IGM Financial Announces Leadership Changes That Provide Strategic Continuity and Position Company for Further Growth
IGM Financial Inc. (IGM) (TSX: IGM) today announced senior leadership changes that will provide business and strategic continuity while further positioning the company for future growth.
Jeff Carney is retiring as President and Chief Executive Officer of IGM Financial and IG Wealth Management for health reasons. James O’Sullivan, formerly Group Head for Canadian Banking at Scotiabank, has been appointed as President and CEO of IGM Financial. Damon Murchison, currently Executive Vice-President, Head of Retail of Mackenzie Investments, has been appointed President and CEO of IG Wealth Management. These changes are effective immediately.
Mr. O’Sullivan is a seasoned financial executive who has held senior leadership roles in wealth and asset management, investment banking, mergers and acquisitions, and finance over the course of his career. He joins following a 30-year career at Scotiabank, where he most recently was responsible for the bank’s Canadian retail and commercial banking and global wealth and asset management activities.
“We are pleased to welcome James O’Sullivan, who is a well-respected industry veteran with a strong background in every aspect of the financial services sector, as the dedicated CEO of IGM Financial,” said Jeffrey Orr, Chairman of IGM Financial. “The Board believes strongly that he has the depth of knowledge and experience to successfully lead IGM forward as it continues to pursue its value creation strategy.”
“I am thrilled to join IGM Financial and build upon their effective strategies and business momentum,” said Mr. O’Sullivan. “I look forward to working with IGM’s talented senior leadership team to continue capitalizing on the recent success of the operating companies and enhancing the capabilities of the group.”
During his tenure, Mr. Carney pursued a client-centric strategy for IG Wealth Management that has improved the company’s competitive position and re-established Mackenzie’s position as an industry leader. He also brought a more integrated approach to creating shareholder value across IGM’s companies through operational effectiveness, technology and other initiatives that position IGM well for future success. Mr. Carney will continue to serve in an advisory capacity to the IGM companies.
“The last seven years have been among the most rewarding of my career and I am proud of what we have achieved for our clients, consultants, employees and shareholders. I have been honoured to lead the IGM companies and to work with an outstanding team, which has delivered exceptional results,” said Mr. Carney. “I have been diagnosed with the early stages of Alzheimer’s disease and while this is a tough decision to make, stepping aside at this time is the right move for both my family and the company. I know I am leaving the leadership of IGM in excellent hands and have great confidence in its future.”
“After more than 30 years in the industry in Canada and the United States and seven years leading IGM companies, Jeff Carney has been an agent for positive change, always with a focus on serving the client,” added Mr. Orr. “Under his visionary leadership, IGM’s companies have emerged stronger and more clearly aligned with their core strength and purpose. Jeff also enhanced the company’s breadth and diversity through its expansion into international markets and fintech. On behalf of the Board and the entire IGM team, we wish Jeff and his family the best. We are profoundly grateful for Jeff’s contributions.”
Mr. Murchison brings 25 years of financial services leadership experience to his new role at IG Wealth Management, including spending the last six years at Mackenzie, where he was responsible for the development and leadership of Mackenzie’s top-performing retail sales organization. He has a broad understanding of advisor-focused financial services in Canada, which will help enhance and broaden IG Wealth Management’s leading financial planning client offering.
Mr. Orr continued, “Damon Murchison’s deep experience across multiple financial services models and strong knowledge of the landscape and competition will be critical for IG Wealth Management’s new business growth. Under his leadership as IG Wealth Management’s dedicated CEO, IG Wealth Management will continue to increase scale and expand its distribution reach, expand financial planning capabilities for existing clients and acquire new high-net worth clients in a dynamic operating environment.”
“I am excited to lead IG Wealth Management into its next phase of growth,” said Mr. Murchison. “I am eager to work closely with the talented IG Wealth Management team and put my experience to work helping broaden IG Wealth Management’s financial planning client offering.”
Mark Kinzel, currently Executive Vice-President of Financial Services for IG Wealth Management, has been appointed Vice-Chair of IG Wealth Management, and will work closely with Mr. Murchison and continue to provide strong leadership and deep knowledge as head of IG Wealth Management’s consultant network.
These leadership changes complement the existing strong IGM leadership team, including Barry McInerney as President and Chief Executive Officer of Mackenzie Investments and Chris Reynolds as President and Chief Executive Officer of Investment Planning Counsel (IPC). Biographies for IGM’s leaders can be viewed here: https://www.igmfinancial.com/en/about-igm-financial/executive-leadership
As part of these changes, James O’Sullivan replaces Jeff Carney as a director of IGM Financial.
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News5 days ago
Millions of people unite around doing good on the 18th International Good Deeds Day held yesterday worldwide
-
Latest News4 days ago
Banxso Acquires Australian ASIC License, Enhancing Its Global Trading Operations
-
Latest News5 days ago
135th Canton Fair Launches a Showcase of Innovative Products of New Collection to Lead Global Market Trends
-
Latest News3 days ago
BMO Announces Election of Board of Directors
-
Latest News5 days ago
BII and FMO back BECIS with joint US$50 million financing facility supporting commercial and industrial renewables sector in South-East Asia
-
Latest News4 days ago
IHG Hotels & Resorts and NOVUM Hospitality sign agreement that doubles IHG’s hotel presence in Germany, launches Holiday Inn – the niu collaboration, and debuts Garner and Candlewood Suites brands
-
Latest News3 days ago
Fiat infrastructure Leader Banxa join forces with Venom foundation in offering Venom-supported tokens access to its global Fiat rails